Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Precision cancer diagnostic test is rapidly emerging in Europe region as new concept and diagnostic test. The diagnostic test majorly focuses on the aspect of molecular analysis for precision medicine and personalized therapies treatment. The new diagnostic test is expected to been an emerging test attributing to specific treatment for individual patient. Moreover, increasing innovation and product launches among key players in the region is further boosting the growth of precision cancer diagnostic tests in Europe region market.
The market is driven by rising prevalence of cancer cases in Europe region. Besides increase in awareness about routine health checkup for early detection of such a diseases is further fueling the demand for precision cancer diagnostic tests market. Also, new product launch in the region is the key factor for the growth of market in the region. For instance in July 2020, AVATAMED and CBmed with AIMEDBIO and Shimadzu Corporation had announced the collaboration in Precision cancer project to discover new technology in cancer research. The medical universities of Graz and Vinna and Health institute of Joanneum Research GmbH had joined had as scientific partner in the project.
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the Europe precision cancer diagnostic tests market. In addition, complete analysis of changes on the Europe precision cancer diagnostic tests market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market.
The precision cancer diagnostic tests market is segmented based on product, application and geography.
The precision cancer diagnostic tests is available in market according to various products including imaging molecular, histology/cytology, tumor marker immunoassays and POC colon cancer tests. Imaging is expected to lead in the precision cancer diagnostic tests market owing to delivering right diagnosis and treatment to patient at right time. Imaging is majorly recognized as potential tool for cancer treatment. Also, imaging helps to identify and diagnose disease precisely on genetic level.
The precision cancer diagnostic tests market find its application in hospital, clinic. Hospital is expected to dominate in precision cancer diagnostic tests market owing developing healthcare facilities and diagnostic method. Besides increasing adoption for diagnosis tool is further boosting the growth of segment in precision cancer diagnostic tests market.
Precision cancer diagnostic tests market is studied for the following countries including Germany, U.K, France, Italy, Spain and Rest of Europe. Germany is expected to lead in the precision cancer diagnostic tests market owing significant number of share in market. The growth in the country is due to emerging healthcare facilities and prevalence of cancer. Besides rising awareness among population for early diagnosis is boosting the growth of precision cancer diagnostic tests market
The key players in precision cancer diagnostic tests market are Biocartis N.V., bioMerieux SA, Epigenomics AG, Menarini Silicon Biosystems SpA, QIAGEN N.V., Randox Laboratories Ltd., Roche Holding AG, Royal Philips N.V. and Siemens AG among others.
January 2021: Roche had announced the CE-IVD launch of automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer. The tool will help to determine and provide right treatment to patient.
February 2020: QIAGEN N.V. had announced the CE marking and the launch of therascreen PIK3CA RGQ PCR Kit in the Europe as an aid in identifying breast cancer patient with PIK3CA mutation
The report analyses the Europe precision cancer diagnostic tests market based on product, application, and geography. The precision cancer diagnostic tests is available in market according to various products including imaging, molecular, histology/cytology, tumor marker immunoassays and POC colon cancer tests. The precision cancer diagnostic tests market find its application in hospital, clinic. Precision cancer diagnostic tests market is studied for the following countries including Germany, U.K, France, Italy, Spain and Rest of Europe among others.
The key players in precision cancer diagnostic tests market are Biocartis N.V., bioMerieux SA, Epigenomics AG, Menarini Silicon Biosystems SpA, QIAGEN N.V., Randox Laboratories Ltd., Roche Holding AG, Royal Philips N.V. and Siemens AG among others.
Why to buy this report:
